Diagnostic Significance of Serum Eotaxin-1 Level in Gastric Cancer Patients

Table 1

The relationship between s-eotaxin-1 levels and pathologic variables in gastric cancer patients.

Variables	𝑛	S-eotaxin, pg/mL median (interquartile range)	𝑃
Age, y
<50	9	81.2 (±13.70)	0.681
50–60	12	76.8 (±19.56)
>60	39	72.2 (±16.20)
Sex
Male	40	76.08 (±16.74)	0.845
Female	20	71.38 (±16.44)
Tumor localization
Cardia/Fundus	25	74.35 (±15.00)	0.354
Corpus	7	79.49 (±18.54)
Antrum	28	73.41 (±17.95)
Differentiation
Well	9	72.08 (±18.53)	0.299
Moderate	12	80.26 (±11.62)
Poor	33	73.65 (±18.35)
Undifferentiated	6	71.38 (±12.86)
Tumor size
≤4 cm	15	78.25 (±14.83)	0.271
4 cm<	39	74.00 (±17.64)
Lymph node metastases (N)
0	9	75.82 (±19.19)	0.823
I	8	80.15 (±14.26)
II	17	74.09 (±14.51)
IIIA	11	70.51 (±20.02)
IIIB	11	75.59 (±19.03)
Positive lymph node ratio (%)
0	9	75.82 (±19.19)	0.547
1–9	10	80.30 (±13.78)
10–25	12	69.67 (±11.74)
26<	25	74.75 (±19.39)
TNM Stage
I/II (early gastric cancer)	17	78.29 (±15.47)	0.427
III/IV (late gastric cancer)	43	73.02 (±17.04)
Perineural invasion
Positive	46	74.40 (±16.67)	0.831
Negative	9	74.12 (±18.14)
Vascular invasion
Positive	46	74.77 (±16.76)	0.898
Negative	9	72.23 (±17.45)